Fulgent Genetics, Inc. (FLGT)

Fulgent Genetics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	289.21	618.97	992.58	421.71	32.53
Revenue Growth (YoY)	-53.27%	-37.64%	135.37%	1196.46%	52.35%
Cost of Revenue	184.76	252.07	215.53	89.81	14.11
Gross Profit	104.46	366.9	777.05	331.91	18.42
Selling, General & Admin	130.47	149.99	75.17	30.17	12.31
Research & Development	41.44	28.91	24.22	11.58	6.54
Other Operating Expenses	128.08	9.47	1.71	0	0
Operating Expenses	299.99	188.37	101.1	41.75	18.85
Operating Income	-195.53	178.53	675.95	290.16	-0.43
Other Expense / Income	-28.86	-6.98	-6.21	3.32	-0.06
Pretax Income	-166.67	185.51	682.16	286.84	-0.37
Income Tax	1.15	42.1	174.8	72.53	0.04
Net Income	-167.83	143.4	507.36	214.31	-0.41
Net Income Growth	-	-71.74%	136.74%	-	-
Shares Outstanding (Basic)	30	30	29	23	19
Shares Outstanding (Diluted)	30	31	31	24	19
Shares Change	-3.81%	-0.04%	28.77%	28.58%	4.07%
EPS (Basic)	-5.63	4.76	17.25	9.44	-0.02
EPS (Diluted)	-5.63	4.63	16.38	8.91	-0.02
EPS Growth	-	-71.73%	83.84%	-	-
Free Cash Flow	5.57	235.16	514.83	105.51	4.34
Free Cash Flow Per Share	0.19	7.81	17.51	4.65	0.23
Gross Margin	36.12%	59.28%	78.29%	78.70%	56.63%
Operating Margin	-67.61%	28.84%	68.10%	68.80%	-1.32%
Profit Margin	-58.03%	23.17%	51.12%	50.82%	-1.26%
Free Cash Flow Margin	1.93%	37.99%	51.87%	25.02%	13.33%
Effective Tax Rate	-	22.70%	25.62%	25.29%	-
EBITDA	-134.12	223.08	694.32	290.21	2.15
EBITDA Margin	-46.37%	36.04%	69.95%	68.82%	6.62%
Depreciation & Amortization	32.56	37.58	12.16	3.37	2.52
EBIT	-166.67	185.51	682.16	286.84	-0.37
EBIT Margin	-57.63%	29.97%	68.73%	68.02%	-1.13%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).